

THE POSSIBILITY OF EMPLOY THE MICRNUCLEUS TEST FOR THE DIAGNOSIS OF THE DOUBT CASES IN THE SCREENING FOR THE DETERMINATION OF BREAST CANCER

Preliminary, and positive results, propose the use of test of the micronucleus , in saliva, for the diagnosis of the cases doubts, detected in screening for breast malignancy

THE CASE DOUBTS – BIRADS 3. PROBABLY BENIGN





BI-RADS ,is a scheme for putting the findings from mammogram screening ,(for breast cancer diagnosis), into a small number of well-defined categories. Although BIRADS started out for use with breast screening mammography, it was later adapted for use with Magnetic Resonance Imaging (MRI) and breast ultrasound (US) as well.

THE BIRADS CASSIFLICATION : 0- incomplete ; 1-negative ;2-benign findings ;**3-PROBABLY BENIGN** ;4-suspicious abnormality ;5-highly suspicious of malignancy ;6-known biopsy with proven

BIRADS 3 is rarely used nowadays, because BIRADS 4 and 5 are categories that lead to biopsies, and breast biopsy to give a definitive diagnosis. BIRADS 3 often indicates the need for a 6-month follow-up mammogram. THIS CAN CAUSE WORRY AND ANXIETY FOR EVERYONE FOR THOSE 6 MONTHS DUE TO THE UNCERTAINTY OF THE SITUATION. BOTH RADIOLOGISTS AND PATIENTS PREFER FAST ANSWERS RATHER THAN HAVING TO WAIT FOR 6 MONTHS

Category 3. Probably Benign

With BI-RADS category 3, a follow-up of 6 months is usually recommended. On the breast cancer screening mammogram there may be a finding of some kind, but the lesion is non-palpable Findings typical of this category include: 1-Clusters of tiny calcifications – round or oval 2-Non-calcified solid nodules (no size limitation but non palpable on physical examination), round, ovoid and well-defined. 3-Selected focal asymmetrical areas of fibroglandular densities (not palpable): This might include concave-outward defined margins, interspersed with fat and without central increased fibular density on two projections. 4- Miscellaneous focal findings, such as a dilated duct or post biopsy architectural distortion without central density 5-Generalized distribution in both breasts. For example, multiple similar lesions with tiny calcifications or nodules distributed randomly In some scenarios a percutaneous biopsy (usually core-needle biopsy) might be considered even for BIRADS category 3. For example, extreme patient anxiety or plans for pregnancy, plans for breast augmentation or reduction surgery, or if synchronous carcinoma is present.

		POSITIVE ↓	NEGATIVE ↓
			
These tiny specs are diffuse Punctuate microcalcifications	This microcalcification is round, but the edges are not sharply defined (indeterminate birads 3)	MICRNUCLEUS MICRNUCLEUS	not MICRNUCLEI

biography

BIOGRAPHY : MENICAGLI LAURA



**2003 -Degree in Medicine and Surgery, University of Milan, Milan, IT
2007**

Specialization in Radiodiagnostics, University of Milan, Milan, IT

PROFESSIONAL EXPERIENCES

**From 2008 reader for the mammographic screening service organized by the ASL Milano2
(Certified Diploma in senology issued by ISPO, Florence, 2006**

**PUBLICATION Collaboration on the research activities of the Radiology Unit of the
IRCCS Policlinic San Donato , with 8 articles published in PubMed indexed journals with
impact factor.**

REFERENCES

1) Verma S D

correlation of morphological markers of chromosomal instability in fine needle aspiration cytology with grade of breast cancer; Cytopathology. 2014 Aug;25(4):259-63

2) Samanta S, Dey P.. Micronucleus and its applications.Review ;Diagn Cytopathol. 2012
Jan;40(1):84-90.

3) Goel S, Bhatia A, Dey P. Spontaneously occurring micronuclei in infiltrating ductal carcinoma of breast: a potential biomarker for aggressive phenotype detection? .Diagn Cytopathol. 2013
Apr;41(4):296-302.

4) .Samanta S, Dey P, Nijhawan R.. The role of micronucleus scoring in fine needle aspirates of ductal carcinoma of the breast ;Cytopathology. 2011 Apr;22(2):111-4.

=

5) Hemalatha A¹, Suresh TN, HarendraKumar ML.. Micronuclei in breast aspirates. Is scoring them helpful ?, J Cancer Res Ther. 2014 Apr-Jun;10(2):309-11

